Patients with COPD and chronic hypercapnic respiratory failure on noninvasive ventilation report similar quality of life ...

Across four prospective U.S. cohorts, 4.5% of those 18-49 years old met criteria for COPD, defined as spirometric airflow ...

The pivotal Phase IIb ALIENTO study met its primary endpoint and showed that astegolimab reduced the annualized exacerbation rate (AER) by a statistically significant 15.4% at 52 weeks, when given ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Urine VOCs are linked to COPD risk and inflammation in NHANES data, suggesting potential for non-invasive screening with ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for the treatment of a chronic lung condition, the drugmaker said on Friday.

Astegolimab from Roche's Genentech fails phase 3 COPD trial, reflecting challenges in monoclonal antibody treatment for the ...

Medicare doesn’t generally cover air purifiers or other devices used for environmental control, such as dehumidifiers and heaters. Learn more.

Ingvar Ambjørnsen, a Norwegian author who mixed a sharp, even dark tone with humor and empathy in works that depicted the ...

The fate of IL-33-targeting astegolimab will be determined by talks with regulators, after Roche AG’s Genentech unit rolled out mixed results from a pair of studies testing the compound vs. placebo on ...

Residents including parents of children who have received care for two conditions — asthma and chronic obstructive pulmonary disease — have been asked to assist in guiding the island’s healthcare ...